"These data further confirm that the profile conferred by our LICA technology demonstrate the potential of these advanced antisense drugs to address broader patient populations in cardiovascular and in non-cardiovascular indications because of the very low volume, infrequent and well-tolerated subcutaneous dosing these drugs can provide." ABOUT AKCEA THERAPEUTICS Akcea Therapeutics is focused on developing and commercializing drugs for patients with serious cardiometabolic diseases caused by lipid disorders. Established as a wholly owned subsidiary of Ionis Pharmaceuticals, Inc., Akcea has a robust portfolio of development-stage drugs covering multiple targets and disease states. The drugs in Akcea's pipeline are designed using Ionis' advanced RNA-targeted antisense technology to address a number of lipid risk factors, including, ApoC-III, triglycerides, Lp(a) and LDL-cholesterol.